Tags

Type your tag names separated by a space and hit enter

Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
Surgery 2006; 140(6):1043-7; discussion 1047-9S

Abstract

BACKGROUND

This study investigated the rate of contralateral papillary thyroid cancer (PTC) in low-risk PTC patients who had completion thyroidectomy, and were referred for radioactive iodine (RAI) therapy. The study sought predictors of contralateral disease and examined the impact of contralateral disease in RAI-treated patients.

METHODS

We reviewed 20 years of data from a prospective registry for 150 patients with PTC. These patients had undergone thyroid lobectomy, followed by completion thyroidectomy, and had been referred for RAI.

RESULTS

Of the 150 patients, 41% had PTC in the contralateral lobe. There was no difference in the rate of contralateral disease in low-risk patients (age <45 years, T1 tumors, lymph node-negative) compared with the remainder. There were no significant differences between patients with or without contralateral disease with respect to primary tumor size, mean age, time to completion thyroidectomy, or metastatic lymph node disease. Logistic regression analyses showed no histologic parameters that correlated with contralateral disease. There were no recurrence or survival differences in patients with or without contralateral disease after resection and RAI.

CONCLUSIONS

The prevalence of tumor in the contralateral lobe of low-risk patients with PTC is significant and warrants consideration for completion thyroidectomy and radioiodine treatment. Our results, however, suggest that contralateral disease does not have an impact on recurrence or survival after treatment.

Authors+Show Affiliations

Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO 63110, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17188155

Citation

Grigsby, Perry W., et al. "Contralateral Papillary Thyroid Cancer at Completion Thyroidectomy Has No Impact On Recurrence or Survival After Radioiodine Treatment." Surgery, vol. 140, no. 6, 2006, pp. 1043-7; discussion 1047-9.
Grigsby PW, Reddy RM, Moley JF, et al. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment. Surgery. 2006;140(6):1043-7; discussion 1047-9.
Grigsby, P. W., Reddy, R. M., Moley, J. F., & Hall, B. L. (2006). Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment. Surgery, 140(6), pp. 1043-7; discussion 1047-9.
Grigsby PW, et al. Contralateral Papillary Thyroid Cancer at Completion Thyroidectomy Has No Impact On Recurrence or Survival After Radioiodine Treatment. Surgery. 2006;140(6):1043-7; discussion 1047-9. PubMed PMID: 17188155.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment. AU - Grigsby,Perry W, AU - Reddy,Rishindra M, AU - Moley,Jeffrey F, AU - Hall,Bruce L, Y1 - 2006/11/01/ PY - 2006/03/28/received PY - 2006/08/08/accepted PY - 2006/12/26/pubmed PY - 2007/1/31/medline PY - 2006/12/26/entrez SP - 1043-7; discussion 1047-9 JF - Surgery JO - Surgery VL - 140 IS - 6 N2 - BACKGROUND: This study investigated the rate of contralateral papillary thyroid cancer (PTC) in low-risk PTC patients who had completion thyroidectomy, and were referred for radioactive iodine (RAI) therapy. The study sought predictors of contralateral disease and examined the impact of contralateral disease in RAI-treated patients. METHODS: We reviewed 20 years of data from a prospective registry for 150 patients with PTC. These patients had undergone thyroid lobectomy, followed by completion thyroidectomy, and had been referred for RAI. RESULTS: Of the 150 patients, 41% had PTC in the contralateral lobe. There was no difference in the rate of contralateral disease in low-risk patients (age <45 years, T1 tumors, lymph node-negative) compared with the remainder. There were no significant differences between patients with or without contralateral disease with respect to primary tumor size, mean age, time to completion thyroidectomy, or metastatic lymph node disease. Logistic regression analyses showed no histologic parameters that correlated with contralateral disease. There were no recurrence or survival differences in patients with or without contralateral disease after resection and RAI. CONCLUSIONS: The prevalence of tumor in the contralateral lobe of low-risk patients with PTC is significant and warrants consideration for completion thyroidectomy and radioiodine treatment. Our results, however, suggest that contralateral disease does not have an impact on recurrence or survival after treatment. SN - 0039-6060 UR - https://www.unboundmedicine.com/medline/citation/17188155/Contralateral_papillary_thyroid_cancer_at_completion_thyroidectomy_has_no_impact_on_recurrence_or_survival_after_radioiodine_treatment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0039-6060(06)00541-1 DB - PRIME DP - Unbound Medicine ER -